Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer

Abroad (travel likely)RecruitingPHASE2, PHASE3

Conditions

Lung Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • The University of Chicago Medical Center, Chicago, Illinois, United States

    Contact: Study coordinator (Christine Bestvina)
  • The Sidney Kimmel Comprehensive Cancer Centre, Baltimore, Maryland, United States

    Contact: Study coordinator (Valsamo Anagnostou) · 410-502-3696
  • Cross Cancer Institute, Edmonton, Alberta, Canada

    Contact: Study coordinator (Nadia Ghazali) · 780 -
  • BCCA - Vancouver, Vancouver, British Columbia, Canada

    Contact: Study coordinator (Cheryl Ho) · 604 877-6000
  • Health Sciences North, Greater Sudbury, Ontario, Canada

    Contact: Study coordinator (Lacey Pitre) · 705 522-6237
  • Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada

    Contact: Study coordinator (Rosalyn Anne Juergens) · 905 387-9711
  • Kingston Health Sciences Centre, Kingston, Ontario, Canada

    Contact: Study coordinator (Mihaela Mates) · 613 549-2631
  • Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

    Contact: Study coordinator (Sara Moore) · 613 737-7700
  • Algoma District Cancer Program, Sault Ste. Marie, Ontario, Canada

    Contact: Study coordinator (Michela Febbraro)
  • University Health Network, Toronto, Ontario, Canada

    Contact: Study coordinator (Adrian Sacher) · 416 946-4501
  • The Jewish General Hospital, Montreal, Quebec, Canada

    Contact: Study coordinator (Jason Scott Agulnik) · 514 398-1444
Study leads
  • Valsamo Anagnostou

    Study Chair

    Johns Hopkins University

  • Sara Moore

    Study Chair

    Ottawa Hospital Research Institute